In the last trading session, 1.8 million shares of the Mersana Therapeutics Inc (NASDAQ:MRSN) were traded, and its beta was 1.60. Most recently the company’s share price was $3.15, and it changed around -$0.1 or -3.08% from the last close, which brings the market valuation of the company to $382.10M. MRSN currently trades at a discount to its 52-week high of $9.62, offering almost -205.4% off that amount. The share price’s 52-week low was $0.80, which indicates that the current value has risen by an impressive 74.6% since then. We note from Mersana Therapeutics Inc’s average daily trading volume that its 3-month average coming to 2.17 million.
Mersana Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.44. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended MRSN as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Mersana Therapeutics Inc is expected to report earnings per share of $Marinus Pharmaceuticals, Inc. for the current quarter.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Instantly MRSN has showed a red trend with a performance of -3.08% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 35.78% year-to-date, but still down -16.89% over the last five days. On the other hand, Mersana Therapeutics Inc (NASDAQ:MRSN) is -34.51% down in the 30-day period.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
Mersana Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 125.00 percent over the past six months and at a 59.46% annual growth rate that is well above the industry average of 13.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.93%.
MRSN Dividends
Mersana Therapeutics Inc’s next quarterly earnings report is expected to be released in May.
